Targeting ONECUT2 itself might be problematic due to its expression also in normal tissues, such as brain, liver, and pancreas but promising results have been observed when targeting ONECUT2-dependent tumor hypoxia [24]. This evidence concerns the gene ONECUT2 and neoplasm.